Mucoresp

**Mucoresp** is an oral fixed-dose respiratory medicine marketed by Azine Healthcare containing ambroxol, salbutamol, and theophylline. Ambroxol provides mucolytic and mucokinetic activity to facilitate clearance of airway secretions, while salbutamol produces beta-2 adrenergic bronchodilation and theophylline contributes bronchodilation through phosphodiesterase inhibition and adenosine-receptor antagonism. Azine Healthcare lists the tablet formulation as ambroxol 30 mg, salbutamol 2 mg, and theophylline 100 mg, and describes use for asthma, bronchitis, COPD, bronchiectasis, emphysema, and other reversible bronchospastic respiratory conditions. ([azinehealthcare.com](https://www.azinehealthcare.com/mucoresp/))

Brand names

Mucoresp

Other names

ambroxol + salbutamol + theophylline